References
- Agar E.:The role of cannabinoids and leptin in neurological diseases. Acta Neurologica Scandinavica, 2015, 132: 371–80.10.1111/ane.12411
- Alexander S.P.:Therapeutic potential of cannabis-related drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015, 64: 157–166.10.1016/j.pnpbp.2015.07.001
- Ameri A.:The effect of cannabinoids on the brain. Progress in neurobiology, 1999, 58: 315–34810.1016/S0301-0082(98)00087-2
- Ames F.R., Cridland S.:Anticonvulsant effect of cannabidiol. South African Medical Journal, 1985, 69: 14.
- Benbadis S.R., Sanchez-Ramos J., Bozorg A., Giarratano M., Kalidas K., Katzin L. et al.:Medical marijuana in neurology. Expert Review of Neurotherapeutic, 2014, 14: 1453–1465.10.1586/14737175.2014.985209
- Brown A.J.:Novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152: 567–575.10.1038/sj.bjp.0707481
- Colasanti B.K., Lindamood C., Craig C.R.:Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacology, Biochemistry, and Behavior, 1982, 16: 573–578.10.1016/0091-3057(82)90418-X
- Consroe P., Benedito M.A., Leite J.R., Carlini E.A., Mechoulam R.:Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. European Journal of Pharmacology, 1982, 83: 293–298.10.1016/0014-2999(82)90264-3
- Consroe P., Wolkin A.:Cannabidiol – antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. The Journal of Pharmacology and Experimental Therapeutics, 1977, 201: 26–32.
- Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R. et al.:Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 1980, 21: 175–185.10.1159/0001374307413719
- Dąbrowska K., Miturska E., Moskalewicz J.:The consequences of marijuana use and abuse – a review. Alkoholizm i Nar-komania, Instytut Psychiatrii i Neurologii, 2012, 25: 167–186.
- Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C. et al.:Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55: 791–802.10.1111/epi.12631470766724854329
- Friedman D., Devinsky O.:“Cannabinoids in the treatment of epilepsy”. N. Engl. J. Med., 2015, 373, 1048–1058.10.1056/NEJMra140730426352816
- Gloss D., Vickrey B.:Cannabinoids for epilepsy. Cochrane Database Sys. Rev. 2014; CD00927010.1002/14651858.CD009270.pub3
- Goldenberg M.M.:Overview of Drugs Used For Epilepsy. Seizures, Etiology, Diagnosis, and Treatment. Pharmacy and Therapeutics, 2010, 35: 392–415.
- Gordon E., Devinsky O.:Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia, 2001, 42: 1266–1272.10.1046/j.1528-1157.2001.19301.x
- Hall.W., Degenhardt L .:Adverse health effects of non-medical cannabis use. Lancet 2009, 17, 374: 1383–139110.1016/S0140-6736(09)61037-0
- Hamerle M., Ghaeni L., Kowski A., Weissinger F., Holtkamp M.:“Cannabis and other illicit drug use in epilepsy patients”. Eur. J. Neurol., 2014, 21: 167–170.10.1111/ene.1208123311572
- Hegde M., Santos-Sanchez C., Hess C.P., Kabir A.A., Garcia P.A.:Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy and Behavior, 2012, 25: 563–566.10.1016/j.yebeh.2012.09.02423159379
- Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R. et al.:Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences USA, 1990, 87: 1932–1936.10.1073/pnas.87.5.1932535982308954
- Hill A.J, Williams C.M., Whalley B.J., Stephens G.J.:Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology and Therapeutics, 2012, 133: 79–97.10.1016/j.pharmthera.2011.09.00221924288
- Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R.:Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 2009, 30: 515–527.10.1016/j.tips.2009.07.00619729208
- Jędrzejko M.:Marihuana fakty. Marihuana mity. Wrocławskie Wydawnictwo Naukowe Atla2, Wrocław 2011.
- Jones N. A., Hill A. J., Smith I., Bevan S. A., Williams C. M., Whalley B. J. et al .:Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. Journal Pharmacology and Experimental Therapeutics, 2010, 332: 569–577.10.1124/jpet.109.159145281983119906779
- Karabowicz P., Grzęda E., Baranowicz-Kuczko M., Malinowska B.:Role of endocannabinoid 2-arachidonylglycerol in the physiology and pathophysiology of the cardiovascular system. Postępy Hig. Med. Dosw (online), 2014, 68: 814–827.10.5604/17322693.110887524934539
- Koppel B.S., Brust J.C.M., Fife T., Bronstei J., Youssof S., Gronseth G. et al:“Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology” Neurology, 2014, 82: 1556–1563.10.1212/WNL.0000000000000363
- Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G. et al.:Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51: 1069–1077.10.1111/j.1528-1167.2009.02397.x
- Löscher W.:Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Research, 2002, 50: 105–123.10.1016/S0920-1211(02)00073-6
- Lozano I.:The therapeutic use of Cannabis sativa L. in Arabic medicine. Journal of Cannabis Therapeutics, 2001, 1: 63–70.10.1300/J175v01n01_05
- Lutz B.:On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochemical Pharmacology, 2004, 68: 1691–1698.10.1016/j.bcp.2004.07.00715450934
- Maa E., Figi P.:The case for medical marijuana in epilepsy. Epilepsia, 2014, 55: 783–786.10.1111/epi.1261024854149
- Mathern G., Nehlig A., Sperling M.:Cannabidiol and medical marijuana for the treatment of epilepsy. Epilepsia, 2014, 55: 781–782.10.1111/epi.1264724854631
- Mechoulam R., Carlini E.A:Toward drugs derived from cannabis. Naturwissenschaften, 1978, 65: 174–179.10.1007/BF00450585351429
- Mechoulam R.:The pharmacohistory of Cannabis sativa. Cannabinoids as therapeutic agents. Boca Raton, 1986, CRC Press; 1–20.10.1201/9780429260667-1
- Mikuriya T.H.:Marijuana in medicine: past, present and future. California Medicine, 1969, 110:34–40.
- Ng S.K., Brust J.C., Hauser W.A., Susser M.:Illicit drug use and the risk of new-onset seizures. American Journal of Epidemiology. 1990, 132: 47–57.10.1093/oxfordjournals.aje.a1156422356813
- O’Shaughnessy W.B.:On the Preparations of the Indian Hemp, or Gunjah. Trans. Med. Phys. Soc. Bombay, 1842, 8: 421–461.
- O’Shaughnessy W.B.:The Bengal Dispensatory and Companion to the Pharmacopoeia. Allen, London 1842.
- Ożarowski M., Mikołajczak P.Ł., Bogacz A., Bartkowiak-Wieczorek J., Kujawski R.:Progress in study of Cannabis sativa leaves extracts without psychotropic cannabinoids in animal model of neuropathic pain. Journal of Medical Science, 2014, 4: 328–33510.20883/medical.e88
- Pacher P., Bátkai S., Kunos G.:The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Review, 2006, 58: 389–462.10.1124/pr.58.3.2
- Pertwee R.G.:The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta 9-tetrahydrocannabivarin. British Journal of Pharmacology, 2008, 153: 199–215.10.1038/sj.bjp.0707442
- Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R. et al.:International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological Reviews, 2010, 62: 588–631.
- Porter B.E., Jacobson C.:Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy and behavior, 2013, 29: 574–577.10.1016/j.yebeh.2013.08.037
- Radwan M.M., Elshohly M.A., Slade D., Ahmed S.A., Khan I.A., Ross S.A.:Biologically active cannabinoids from high potency Cannabis sativa. Journal Natural Products, 2009, 72: 906–911.10.1021/np900067k
- Reynolds J.R.:Therapeutic uses and toxic effects of Cannabis indica. Lancet, 1890, 1: 637–638.10.1016/S0140-6736(02)18723-X
- Russo E.B.:Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 2011, 163: 1344–1364.10.1111/j.1476-5381.2011.01238.x316594621749363
- Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J.:The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152: 1092–1101.10.1038/sj.bjp.0707460209510717876302
- Rymanowski M.:Cannabis – review of the issues related to determination of the total content of delta-9-tetrahydrocannabinol (Δ-9-THC) and delta 9-tetrahydrocannabinolic acid (Δ-9-THCA-A). Problemy Kryminalistyki, 2014, 285: 1–18.10.34836/pk.2014.285.1
- Santos R.G., Hallak J.E., Leite J.P., Zuardi A.W., Crippa J.A.:Phytocannabinoids and epilepsy. Journal Clinical Pharmacy and Therapeutics, 2015, 40: 135–143.10.1111/jcpt.1223525475762
- Shore D.M., Reggio P.H .:The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Frontiers in Pharmacology, 2015, 6:69. doi: 10.3389/fphar.2015.0006910.3389/fphar.2015.00069439772125926795
- Shaw J.:On the use of Cannabis indica in tetanus hydrophobia, and in cholera with remarks on its effects. Madras Med. J., 1843, 5: 74–80.
- Stanley C.P., Hind W.H., Tufarelli C., O’Sullivan S.E.:Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovascular Research, 2015, 107: 568–578.10.1093/cvr/cvv179454014426092099
- Sugiura T., Waku K .:Cannabinoid receptors and their endogenous ligands. Journal of Biochemistry, 2002, 132: 7–12.10.1093/oxfordjournals.jbchem.a00320012097154
- Szaflarski J.P., Bebin E.M.:Cannabis, cannabidiol, and epilepsy – from receptors to clinical response. Epilepsy Behavior, 2014, 41: 277–82.10.1016/j.yebeh.2014.08.13525282526
- Szukalski B.:Kannabinoidy. Kompendium wiedzy o środkach uzależniających. Wyd. Instytutu Psychiatrii i Neurologii, Warszawa 2005.
- Trembly B., Sherman M.:Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ‘90 International Conference on Cannabis and Cannabinoids,199O July 8–11, Kolympari, Crete. International Association for Cannabinoid Medicines, 1990: section 2, p. 5.
- Turkanis S.A., Smiley, K.A., Borys H.K., Olsen D.M., Karler R.:An Electrophysiological Analysis of the Anticonvulsant Action of Cannabidiol on Limbic Seizures in Conscious Rats. Epilepsia, 1979, 20: 351–363. doi:10.1111/j.1528-1157.1979.tb04815.x10.1111/j.1528-1157.1979.tb04815.x477630
- Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., DeLorenzo R.J.:The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. The Journal of Pharmacology and Experimental Therapeutics, 2003, 307: 129–137.10.1124/jpet.103.05192012954810
- Wilkinson J.D., Whalley B.J., Baker D., Pryce G., Constanti A., Gibbons S. et al.:Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? The Journal of Pharmacy and Pharmacology, 2003, 55: 1687–1694 doi:10.1211/002235702230410.1211/002235702230414738597
- Wolff V., Armspach J.P., Lauer V., Rouyer O., Bataillard M. et al.:Cannabis-related stroke: myth or reality? Stroke, 2013, 44: 558–563.10.1161/STROKEAHA.112.67134723271508
- Zhornitsky S., Potvin S.:Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel), 2012, 5: 529–552.10.3390/ph5050529376364924281562
- Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimaraes F.S.:Cannabidiol, Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res., 2006, 39: 421–429.10.1590/S0100-879X200600040000116612464